A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis

In brief

An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis

Key facts

Study ID
NCT07054515
Run by
Azafaros B.V.
People needed
147
Starts
2025-06-30
Expected to finish
2028-06-14
Last updated by the study team
2026-08-04

Who can join

Age: 4 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.